Preferences help
enabled [disable] Abstract
Number of results
2017 | 64 | 2 | 295-299
Article title

MMP-10, MMP-7, TIMP-1 and TIMP-2 mRNA expression in esophageal cancer

Title variants
Languages of publication
Introduction: Tissue inhibitors of metalloproteinases (TIMP) and the matrix metalloproteinases (MMP) are involved in the spread of cancer. Methods: We have evaluated the matrix metalloproteinases' (MMP-10, MMP-7) and their inhibitors' (tissue inhibitors of metalloproteinases - TIMP-1, TIMP-2) mRNA expression in 61 esophageal cancer samples from patients who had undergone surgery, by using real-time quantitative RT-PCR, and correlated the results with the patient clinicopathologic features. Results: MMP-10, MMP-7, TIMP-1, TIMP-2 were overexpressed in 73%, 85%, 55% and 42% of esophageal cancer samples, respectively. The expression of MMP-10, TIMP-1, and TIMP-2 correlated with the tumor size. The MMP-7 overexpression was associated with the tumour stage (I, II vs III, p=0.05) and lymph node metastasis (N0 vs N1, p=0.037). Conclusions: We conclude that in the resected esophageal cancer an increased mRNA expression of MMP-7, MMP-10 and TIMP-1 correlated with clinicopathologic features. We suggest that these genes may play a role during progression of the disease.
Physical description
  • Department of Clinical Molecular Biology, Medical University of Bialystok, Bialystok, Poland
  • Department of Clinical Molecular Biology, Medical University of Bialystok, Bialystok, Poland
  • Department of Statistic and Medical Informatics, Medical University of Bialystok, Bialystok, Poland
  • Department of Thoracic Surgery, Medical University of Bialystok, Bialystok, Poland
  • Department of Thoracic Surgery, Medical University of Bialystok, Bialystok, Poland
  • Department of Thoracic Surgery, Medical University of Bialystok, Bialystok, Poland
  • Department of Clinical Molecular Biology, Medical University of Bialystok, Bialystok, Poland
  • Department of Thoracic Surgery, Medical University of Bialystok, Bialystok, Poland
  • Alakus H, Grass G, Hennecken J, et al. (2008) Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histol Histopathol 23: 917-923.
  • Baker AH, Edwards DR, Murphy G. (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115: 3719-3727. doi: 10.1242/jcs.00063.
  • Bollschweiler E, Hölscher AH (2007) Prognosis of early esophageal cancer: differences between squamous cell carcinoma and adenocarcinoma. Ann Surg 245: 334-339. doi: 10.1097/01.sla.0000253072.33351.a4.
  • Borchers AH, Powell MB, Fusenig NE, Bowden GT. (1994) Paracrine factor and cell-cell contact-mediated induction of protease and c-ets gene expression in malignant keratinocyte/dermal fibroblast cocultures. Exp Cell Res 213: 143-147. doi: 10.1006/excr.1994.1183.
  • Deryugina EI, Quigley JP. (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34. doi: 10.1007/s10555-006-7886-9.
  • Edge SB, ByrD DR, Compton CC, Fritz AG, Greene FL, Trotti A. (2010) Esophagus and esophagogastric junction. In AJCC cancer staging manual. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL eds. 7th edn, pp 103-107. New York: Springer.
  • Gu ZD, Li JY, Li M, et al. (2005) Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol 100: 1835-1843. doi: 10.1111/j.1572-0241.2005.50018.x.
  • Jian GY, Goldberg ID, Shi YE (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21: 2245-2252. doi: 10.1038/sj.onc.1205291.
  • Juchniewicz A, Niklińska W, Kowalczuk O, et al. (2015) Prognostic value of vascular endothelial growth factor-C and podoplanin mRNA expression in esophageal cancer. Oncol Lett 10: 3668-3674. htpp://
  • Kähäri VM, Saarialho-Kere U (1999) Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 31: 34-45.
  • Kollarova H, Machova L, Horakova D, Janoutova G, Janout V. (2007) Epidemiology of esophageal cancer - an overview article. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 151: 17–20.
  • Kozłowski M, Laudański W, Mroczko B, Szmitkowski M, Milewski R, Łapuć G, (2013) Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients. Adv Med Sci 58: 227-234. doi: 10.2478/ams-2013-0017.
  • Leeman MF, Curran S, Murray GI. (2003) New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 201: 528-534. doi: 10.1002/path.1466.
  • Lozano R, Naghavi M, Foreman K, et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2095-2128. doi: 10.1016/S0140-6736(12)61728-0.
  • Lynch CC, Matrisian LM. (2002) Matrix metalloproteinases in tumor-host cell communication. Differentiation 70: 561-573. doi: 10.1046/j.1432-0436.2002.700909.x.
  • Mimori K, Mori M, Shiraishi T, et. al. (1997) Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 76: 531-536.
  • Miyata Y, Iwata T, Ohba K, et al. (2006) Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis. Clin Cancer Res 12: 6998-7003. doi: 10.1158/1078-0432.CCR-06-1626.
  • Mori M, Mimori K, Sadanaga N, et al. (2000) Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in esophageal carcinoma. Int J Cancer 88: 575-578. doi: 10.1002/1097-0215(20001115)88:4<575::AID-IJC9>3.0.CO;2-C.
  • Mroczko B, Groblewska M, Łukaszewicz-Zajac M, Bandurski R, Kedra B, Szmitkowski M. (2009) Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients. Clin Chem Lab Med 47: 1133-1139. doi: 10.1515/CCLM.2009.253.
  • Mroczko B, Łukaszewicz-Zając M, Wereszczyńska-Siemiątkowska U, et al. (2009) Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 38: 613-618. doi: 10.1097/MPA.0b013e3181a488a0.
  • Mukherjee S, Roth MJ, Dawsey SM, et al. (2010) Increased matrix metalloproteinase activation in esophageal squamous cell carcinoma. J Transl Med 8: 91. doi: 10.1186/1479-5876-8-91.
  • Nabeshima K, Inoue T, Shimao Y, Sameshima T (2002) Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 52: 255-264. doi: 10.1046/j.1440-1827.2002.01343.x.
  • Rydlova M, Holubec LJR, Ludvikova MJR, et al. (2008) Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res 28: 1389-1397.
  • Salmela MT, Karjalainen-Lindsberg ML, Puolakkainen P, Saarialho-Kere U (2001) Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's esophageal adenocarcinoma. Br J Cancer 85: 383-392. doi: 10.1054/bjoc.2001.1929.
  • Samantaray S, Sharma R, Chattopadhyaya TK, Gupta SD, Ralhan R (2004) Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 130: 37-44. doi: 10.1007/s00432-003-0500-4.
  • Sato H, Kida Y, Mai M, Endo Y, Sasaki T (1992) Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 7: 77-83.
  • Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.
  • Sharma R, Chattopadhyay TK, Mathur M, Ralhan R (2004) Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology 67: 300-309. doi: 10.1159/000081331.
  • Stetler-Stevenson WG (2001) The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am 10: 383-392.
  • Szarvas T, Becker M, Vom Dorp F, et al. (2010) Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci 101: 1300-1308. doi: 10.1111/j.1349-7006.2010.01506.x.
  • Tanioka Y, Yoshida T, Yagawa T, et al. (2003) Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer 89: 2116-2121. doi: 10.1038/sj.bjc.6601372.
  • Vallböhmer D, Brabender J, Metzger R, Hölscher AH (2010) Genetics in the pathogenesis of esophageal cancer: possible predictive and prognostic factors. J Gastrointest Surg 14 Suppl 1: S75-S80. doi: 10.1007/s11605-009-1021-5.
  • Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839. doi: 10.1161/01.RES.0000070112.80711.3D.
  • Yamamoto H, Adachi Y, Itoh F, et al. (1999) Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 59(14): 3313-3316.
  • Yamashita K, Mori M, Shiraishi T, Shibuta K, Sugimachi K (2000) Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 6: 1169-1174.
  • Zhang J, Jin X, Fang S, et al. (2005) The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis 26: 1748-1753. doi: 10.1093/carcin/bgi144.
  • Zhou JH, Zhang B, Kernstine KH, Zhong L. (2011) Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastroenterol 17: 1373-1378. doi: 10.3748/wjg.v17.i10.1373.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.